+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Alzheimers Disease Diagnostic Market size was valued at USD 4.5 Billion in 2022. The Alzheimers Disease Diagnostic market industry is projected to grow from USD 4.8 Billion in 2023 to USD 8.6 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.50% during the forecast period (2023 - 2032). Investments in biomarkers for drug research, an increase in pipeline drug development, and an increase in chronic diseases like dementia, are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report.
Source: Secondary Research, Primary Research, Research Layer Database and Analyst Review
The primary drivers of the global market for Alzheimer's disease diagnostics include the rise of chronic diseases like dementia, investments in biomarkers for drug development, pipeline drug development, an expansion of treatment choices, and improved diagnostic techniques for early disease identification. According to the World Alzheimer Report, 50 million people would be living with dementia and Alzheimer's disease globally in 2022. And it is anticipated that by 2050, this figure would rise to 152 million. The world's ageing population is also a significant factor in the growth of the Alzheimer's disease diagnostic market in the upcoming years.
Both a rise in chronic diseases like dementia and an increase in life expectancy have contributed to a significant expansion in the older population. Government initiatives, healthcare providers, and academic organisations are spending a lot of money on research and development to uncover the condition's primary treatment. The number of clinical studies and pathological investigations with research and development is likely to rise throughout the projected period, which would lead to an expansion in the market for diagnosing Alzheimer's disease. As a result of improvements in diagnostic technologies and continuous research programmes, businesses are expanding their product offers and producing new products. Along with other company development tactics including mergers and acquisitions, strategic collaborations, and new investments into other sectors, this is anticipated to contribute to the market for diagnostics for Alzheimer's disease growing during the next years.
The primary factors driving the expansion of the market for diagnostics for the disease are the expanding usage of biomarkers in Alzheimer's diagnosis and pharmaceutical development as well as the rising prevalence of the condition internationally. For instance, a WHO report from September 2022 stated that there are over 55 million dementia sufferers globally, and that 10 million new cases are detected year. According to the WHO, Alzheimer's disease causes 60–70% of all cases of dementia, making it the most common kind. Additionally, due to the increasing prevalence of Alzheimer's disease worldwide, both government and non-government organisations are investing heavily in the development of diagnostics and treatments for the condition, which could accelerate the market's growth. In June 2021, the ADDF Diagnostics Accelerator, for instance, announced the start of four new research projects to develop digital biomarkers for the diagnosis of Alzheimer's disease. Additionally, it is predicted that these expenditures will encourage market expansion.
Over the course of the forecast period, other business expansion initiatives such as mergers and acquisitions, strategic collaboration, and new investments into other companies are expected to complement the development of the Alzheimer's disease diagnostics and therapeutics market, in addition to the advancement of diagnostic technologies and ongoing research activities in the area. For instance, Brigham and Women's Hospital in Boston, United States, started a clinical research in November 2021 to look into the efficacy and safety of a novel nasal vaccination for Alzheimer's disease. Since such therapeutic advancement leads to better Alzheimer's drugs, the market under study is expanding. Thus, driving the Alzheimers Disease Diagnostic market revenue.
The global Alzheimers Disease Diagnostic market segmentation, based on Type, includes Early Onset Alzheimers, Late Onset Alzheimers, Familial Alzheimers Disease, and Others. Early Onset Alzheimers segment dominated the global market in 2022. This is due to the growing demand for diagnostic tests to detect Alzheimer's disease at an early stage.
The global Alzheimers Disease Diagnostic market segmentation, based on Diagnostic Tests, includes Genetic Testing, Neurological Exam, Mini Mental State Exam (MMSE), Brain Imaging, and Others. Neurological exam segment dominated the global market in 2022. imaging the brain PET is a nuclear molecular imaging technique that helps to visualize in vivo cellular metabolism by using radiopharmaceuticals (tracers) that have been tagged with a positron-emitting isotope. The method assists in assessing the rate of uptake of such radiotracers in specifically chosen cells throughout a patient's body by detecting the positrons generated during the radiotracer decay. Positron emission tomography (PET) is a key tool in the management of Alzheimer's disease (AD).
The global Alzheimers Disease Diagnostic market segmentation, based on End User, includes Clinic, Hospital, Diagnostic Center, and Others. Hospital segment dominated the global Alzheimers Disease Diagnostic market in 2022. The brain scanned Using radiopharmaceuticals (tracers) that have been labelled with a positron-emitting isotope, PET is a nuclear molecular imaging technique that aids in visualizing in vivo cellular metabolism. The method assists in assessing the rate of uptake of such radiotracers in specifically chosen cells located throughout a patient's body by detecting the positrons generated during the radiotracer decay. Positron emission tomography (PET) is an important method used in the management of Alzheimer's disease (AD).
Figure 1: Global Alzheimers Disease Diagnostic Market, by End User, 2022 & 2032 (USD Billion)
Download Free Sample to learn more about this report.
Source: Secondary Research, Primary Research, Research Layer Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Alzheimers Disease Diagnostic Market dominated this market in 2022 (45.80%). The market is growing as a result of the ongoing advancements in Alzheimer's disease treatment research. In June 2021, the U.S. FDA designated the anti-amyloid beta protofibril antibody lecanemab (BAN2401) as a breakthrough therapy for the treatment of Alzheimer's disease. It is a creation of Biogen and Eisai Co., Ltd. Additionally, growing government spending and efforts are predicted to hasten industry expansion. Further, the U.S. Alzheimers Disease Diagnostic market held the largest market share, and the Canada Alzheimers Disease Diagnostic market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: GLOBAL ALZHEIMERS DISEASE DIAGNOSTIC MARKET SHARE BY REGION 2022 (USD Billion)
Download Free Sample to learn more about this report.
Source: Secondary Research, Primary Research, Research Layer Database and Analyst Review
Europe Alzheimers Disease Diagnostic market accounted for the healthy market share in 2022. The increasing prevalence of Alzheimer's disease in Europe highlights the need of diagnostics in the field. The key factors influencing the importance of region in the overall sector are the significant technology advancements. Further, the German Alzheimers Disease Diagnostic market held the largest market share, and the U.K Alzheimers Disease Diagnostic market was the fastest growing market in the European region.
The Asia Pacific Alzheimers Disease Diagnostic market is expected to register significant growth from 2023 to 2032. This is brought on by growing public awareness and more research into developing new drugs to treat AD. By 2058, there will likely be 1.1 million dementia sufferers in Australia, up from the expected 487,500 in 2022. Dementia is the second most common cause of mortality in Australia. Moreover, China’s Alzheimers Disease Diagnostic market held the largest market share and the Indian Alzheimers Disease Diagnostic market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Alzheimers Disease Diagnostic market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Alzheimers Disease Diagnostic industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Alzheimers Disease Diagnostic industry to benefit clients and increase the market sector. In recent years, the Alzheimers Disease Diagnostic industry has offered some of the most significant advantages to medicine. Major players in the Alzheimers Disease Diagnostic market, including Eli Lilly and Company, TauRx (Republic of Singapore), Alector LLC, Accera, Inc., Treventis Corporation, Neuro-Bio Ltd, Cognition Therapeutics Inc, Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., Allergan PLC, and Daiichi Sankyo Co., are attempting to increase market demand by investing in research and development End Users.
Eisai Co Ltd (Eisai), a pharmaceutical company, discovers, develops, produces, and markets pharmaceuticals, including over-the-counter, generic, and prescription medications. The organization's research focus areas are oncology and neurology. The proton pump inhibitors Pariet/AcipHex, Aricept, perampanel, Halaven, an anti-cancer drug, and Fycompa tablets for the treatment of peripheral neuropathy and epilepsy are among the primary products made by Eisai. Eisai is a multinational company with operations across the Americas, Asia, Latin America, EMEA, and Oceania. In addition to having international sales offices in the US, Germany, France, China, and South Korea, it also has production facilities in Japan, the UK, China, and India, as well as research and development facilities in Japan, the US, and the UK. Eisai is based in Tokyo, the capital of Japan. For the treatment of mild cognitive impairment (MCI) brought on by Alzheimer's disease and mild Alzheimer's disease, lecanemab, an experimental anti-amyloid beta (A) protofibril antibody, is being studied. Esai Co., Ltd. and Biogen Inc. released encouraging topline findings from Eisai's major international Phase 3 confirmatory Clarity AD clinical trial in September 2022.
Eli Lilly and Co. (Lilly), a healthcare company, is engaged in the development, production, and marketing of healthcare-related goods. The company sells drugs for cardiovascular diseases, cancer, men's health, musculoskeletal disorders, endocrinology, and neurological conditions. The business distributes its pharmaceutical and healthcare products through independent wholesale distributors. Lilly works on research and development projects to uncover and offer innovative medicines. It also uses sales representatives and joint ventures with other pharmaceutical companies to advertise its products. The company also markets its products in the North America, South America, Europe, South Asia, Middle East, Africa, and North Asia-Pacific regions. Lilly's headquarters are in Indianapolis, Indiana, a city in the United States. In December 2018, Eli Lilly and Company and AC Immune collaborated to develop a new Alzheimer's disease drug using AC Immune's Morphomer technology.
· Eli Lilly and Company
· TauRx (Republic of Singapore)
· Alector LLC
· Accera, Inc.
· Treventis Corporation
· Neuro-Bio Ltd
· Cognition Therapeutics Inc
· Hoffmann-La Roche
· Novartis AG
· Merck & Co.
· Pfizer Inc.
· Allergan PLC
· Daiichi Sankyo Co.
October 2021: Salk Institute began a phase 1 clinical study to assess the novel Alzheimer's drug CMS121's safety in human subjects.
· Early Onset Alzheimers
· Late Onset Alzheimers
· Familial Alzheimers Disease
· Others
· Genetic Testing
· Neurological Exam
· Mini Mental State Exam (MMSE)
· Brain Imaging
· Others
· Clinic
· Hospital
· Diagnostic Center
· Others
· North America
- U.S.
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
|
Report Attribute/Metric |
Details |
|
Market End User 2022 |
USD 4.5 Billion |
|
Market End User 2023 |
USD 4.8 Billion |
|
Market End User 2032 |
USD 8.6 Billion |
|
Compound Annual Growth Rate (CAGR) |
8.50% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Type, Diagnostic Tests, End User, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
Eli Lilly and Company, TauRx (Republic of Singapore), Alector LLC, Accera, Inc., Treventis Corporation, Neuro-Bio Ltd, Cognition Therapeutics Inc, Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., Allergan PLC, and Daiichi Sankyo Co. |
|
Key Market Opportunities |
Extensive efforts and investments in Alzheimers disease diagnostics R&D field |
|
Key Market Dynamics |
Growing chronic diseases like dementia, investment in biomarkers for drug development, and increasing pipeline drug development |
As per Research Layer the global Alzheimers Disease Diagnostic Market size was 4.5 US Dollars in 2022 to 8.6 US Dollars by 2032.
The global market is projected to grow at a CAGR of 8.50% during the forecast period, 2023-2032
North America had the largest share in the global market
The key players in the market Eli Lilly and Company, TauRx (Republic of Singapore), Alector LLC, Accera, Inc., Treventis Corporation, Neuro-Bio Ltd, Cognition Therapeutics Inc, Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., Allergan PLC, and Daiichi Sankyo Co.
The Early Onset Alzheimers Type dominated the market in 2022.
The Brain Imaging Diagnostic Tests had the largest share in the global market.
Report Code :
RL6538
Published on :
Aug 2023
Request a Free Sample Report
Speak to Analyst